Thomas Flaten
Stock Analyst at Lake Street
(2.03)
# 2,824
Out of 5,182 analysts
43
Total ratings
33.33%
Success rate
-0.32%
Average return
Main Sectors:
Stocks Rated by Thomas Flaten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASRT Assertio Holdings | Downgrades: Hold | $45 → $18 | $18.02 | -0.11% | 4 | Apr 9, 2026 | |
| EVAX Evaxion | Maintains: Buy | $11 → $9 | $4.04 | +122.77% | 4 | Mar 9, 2026 | |
| IMDX Insight Molecular Diagnostics | Maintains: Buy | $8 → $12 | $3.17 | +278.55% | 1 | Feb 17, 2026 | |
| CSTL Castle Biosciences | Maintains: Buy | $35 → $52 | $23.13 | +124.82% | 7 | Jan 12, 2026 | |
| PTHS Pelthos Therapeutics | Initiates: Buy | $50 | $22.58 | +121.43% | 1 | Dec 3, 2025 | |
| CNTB Connect Biopharma Holdings | Initiates: Buy | $9 | $2.82 | +219.15% | 1 | Dec 1, 2025 | |
| MDXH MDxHealth | Maintains: Buy | $7 → $9 | $2.04 | +342.26% | 1 | Nov 13, 2025 | |
| HROW Harrow | Maintains: Buy | $42 → $70 | $35.93 | +94.82% | 1 | Sep 29, 2025 | |
| DERM Journey Medical | Maintains: Buy | $9 → $13 | $5.17 | +151.45% | 2 | Aug 13, 2025 | |
| RPID Rapid Micro Biosystems | Initiates: Buy | $8 | $2.12 | +277.36% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $14 | $5.99 | +133.72% | 2 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.55 | +213.73% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $40 | $13.13 | +204.65% | 1 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $17 → $9 | $9.60 | -6.25% | 5 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $4.08 | +96.08% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $6.02 | +49.50% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $11 | $3.49 | +215.19% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $25 | $19.74 | +26.65% | 2 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14,400 → $1,440 | $0.46 | +309,910.76% | 2 | Nov 17, 2022 |
Assertio Holdings
Apr 9, 2026
Downgrades: Hold
Price Target: $45 → $18
Current: $18.02
Upside: -0.11%
Evaxion
Mar 9, 2026
Maintains: Buy
Price Target: $11 → $9
Current: $4.04
Upside: +122.77%
Insight Molecular Diagnostics
Feb 17, 2026
Maintains: Buy
Price Target: $8 → $12
Current: $3.17
Upside: +278.55%
Castle Biosciences
Jan 12, 2026
Maintains: Buy
Price Target: $35 → $52
Current: $23.13
Upside: +124.82%
Pelthos Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $50
Current: $22.58
Upside: +121.43%
Connect Biopharma Holdings
Dec 1, 2025
Initiates: Buy
Price Target: $9
Current: $2.82
Upside: +219.15%
MDxHealth
Nov 13, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $2.04
Upside: +342.26%
Harrow
Sep 29, 2025
Maintains: Buy
Price Target: $42 → $70
Current: $35.93
Upside: +94.82%
Journey Medical
Aug 13, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $5.17
Upside: +151.45%
Rapid Micro Biosystems
Jul 28, 2025
Initiates: Buy
Price Target: $8
Current: $2.12
Upside: +277.36%
Jul 18, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $5.99
Upside: +133.72%
Jul 1, 2025
Initiates: Buy
Price Target: $8
Current: $2.55
Upside: +213.73%
May 14, 2025
Maintains: Buy
Price Target: $60 → $40
Current: $13.13
Upside: +204.65%
Mar 20, 2025
Downgrades: Hold
Price Target: $17 → $9
Current: $9.60
Upside: -6.25%
Mar 7, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $4.08
Upside: +96.08%
Jan 8, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $6.02
Upside: +49.50%
Mar 5, 2024
Maintains: Buy
Price Target: $19 → $11
Current: $3.49
Upside: +215.19%
Aug 9, 2023
Maintains: Buy
Price Target: $34 → $25
Current: $19.74
Upside: +26.65%
Nov 17, 2022
Maintains: Buy
Price Target: $14,400 → $1,440
Current: $0.46
Upside: +309,910.76%